Marina T Alamanou
Marina T Alamanou
Life Science Consultant
AI Pharma Deals: Merck and AI Startups
Pharma and AI Drug Discovery According to ResearchAndMarkets.com, the global AI in pharma market is expected to grow from $0.91 billion in 2020 to $1.27 billion in 2021 at a compound annual growth rate (CAGR) of 39%, eventually reaching $5.94 billion in 2025 at a CAGR of 47% (Source).
AI startups transforming dissemination of biomedical science
Where does research begin? When it comes to producing biomedical scientific knowledge (research, research papers, and lead-generators for pharma) the best thing that describes the relationship between academia and pharma is a tango. A dance that requires two partners moving in relation to each other, sometimes in tandem and sometimes in opposition.
From Cuju to Blockchain and AI
Football⚽️: The Origin Historians suggest that the history of football (soccer) dates back as far as 2500 B.C. During that time, the Chinese (Cuju), the Japanese (Kemari), the Greeks (Episkyros) and the Romans (Harpastum) all appear to have partaken in games involving a ball and feet. With the Chinese game of Cuju - meaning “kicking the ball” that might have been a training exercise for soldiers - being the most relevant of these ancient games to our modern day football.
Longevity tips and AI startups
Aging Aging (spelled ageing in British English) is the process of becoming older, that involves a series of functional changes that appear over time and are not the result of illness or accident, but occur as a consequence of accumulating disorders in the body’s structure and functions. It is an unpreventable chronological, social and biological process and is genetically determined and environmentally modulated. Let's see now how aging and life expectancy are affected.
Artificial Intelligence in Drug Discovery: An overview
According to Markets and Markets, the global AI drug discovery market is projected to reach $ 1,434 million by 2024 from $ 259 million in 2019, at a CAGR of 40.8% during the forecast period 2019–2024.
Polywork: a new professional and social network for polyworkers
A new space of influencers, writers, investors, developers, designers, content creators, lifestyle entrepreneurs, hustlers, models, musicians and any kind of polyworker
AI Pharma Deals: Novartis and AI Startups
Novartis in the era of Artificial Intelligence Big pharmas have been actively pursuing AI startups lately and some companies that lead the way in terms of the number of AI partnerships are Pfizer and AI Startups (Pfizer mentioned AI six times in its corporate reports between January 2020 and June 2021) AstraZeneca and AI Startups (AstraZeneca is spearheading the AI hiring race advertising for 676 new jobs between January 2020 and June 2021), Bayer and AI Startups (an AI leader with seven new AI deals announced from January 2020 to June 2021), Takeda and AI Startups (Takeda Pharmaceutical Co Ltd was third with 545 new job listings in the AI hiring race) and GSK and AI Startups. Other pharmaceutical companies that have recently forged deals in this area include Novartis, Bristol Myers Squibb (BMS), Roche, Janssen, Merck, Boehringer Ingelheim and Sanofi. But today, I am going to talk about Novartis.
Gigantum: Decentralised Data Science
Gigantum: a web application for better collaboration while making reproducible research easier The scientific community has a big problem, and its called reproducibility crisis. Whether you are a biomedical scientist or a computer scientist, eventually you will come to understand that the biggest challenge you will face in your carreer is to: "Reproduce the results from your own scientific paper".